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Editorials

EDITORIALS
Antibiotics to promote growth in children?
Worth studying in highly selected children, with a close eye on potential harms
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Overt infections are a leading cause of death worldwide in
children under 5,1 and strategies to prevent and treat infections
are a cornerstone of child survival programmes. Recent
assessments suggest that despite a net increase in the size of
birth cohorts, the number of children dying before their fifth
birthday has fallen to 6.6 million (uncertainty range 6.3-7.0
million) per year, a 45% reduction from almost 12 million deaths
in 1990.2 In contrast, the fall in undernutrition has been modest
at best. An estimated 165 million children under 5 were stunted
in 2011 and an estimated 52 million severely wasted; almost
45% of the current burden from child mortality in under 5s can
be attributed to malnutrition.3 Although many risk factors for
early child mortality are well recognised, the mechanisms
underlying chronic enteropathy and growth failure among
children in low and middle income countries remain uncertain.4

In a linked paper, Gough and colleagues (doi:10.1136/bmj.
g2267) report a systematic review of 10 trials looking for
associations between antibiotics, given for a variety of
indications, and growth in childhood.5 The review included 4316
children (age range 1 month to 12 years) from low and middle
income countries. The authors’ analysis using random effects
models suggests that antibiotic use was associated with increased
mean height or linear growth (extra linear growth 0.04
cm/month, 95% confidence interval 0.00 to 0.07) and an extra
23.8 g weight gain per month (95% confidence interval 4.3 to
43.3 g). The authors recommend further evaluation of the growth
promoting effect of antibiotics and speculate that the effects
may operate through reduction in subclinical infections and
beneficial effects on intestinal microbiota.

Several limitations must be considered when interpreting these
findings. The 10 included trials were diverse, spanned almost
60 years, and studied a mixed bag of antimicrobial agents and
dosages. Some drugs were for prevention, others targeted
treatment of specific infections. Treatment periods and follow-up
periods varied widely (5 to 575 days and 7 to 658 days,
respectively), as did the type of infection under study and the
age of the children. The analysis did not take into account the
different drivers of growth, especially linear growth, among
children aged 1-24 months and those of school age. Finally, the
inclusion of trials of metronidazole for giardiasis is questionable,

given the recent findings from a large multicountry study of the
causes of diarrhoea suggesting that the organism may not be
pathogenic.6

Despite these caveats, there is increasing interest in the potential
role of antibiotic treatment as an adjunct to other interventions,
especially nutrition rehabilitation. In a recent study from
Malawi,7 stable but severely malnourished children given
antibiotics (amoxicillin or cefdinir) for a week in addition to
nutritional rehabilitation had significantly better recovery rates
and lower mortality than controls given nutritional rehabilitation
alone. An important trial of mass treatment with erythromycin
(20 mg/kg) in rural Ethiopia also showed a 49% reduction in
childhood mortality (cluster adjusted odds ratio for childhood
mortality in the intervention communities compared with control
communities, 0.51, 95% confidence interval 0.29 to 0.90).8 In
a trial from Zimbabwe and Uganda, children with HIV who
stopped taking daily cotrimoxazole did significantly worse
(higher rates of hospital admissions or death) than children who
continued taking it. All participants were aged 3 or more and
had been taking antiretroviral agents for at least 96 weeks.9

Given the evidence of benefits on survival, it is reasonable to
anticipate potential benefits of antibiotic treatment on relevant
morbidity patterns and possibly growth. The potential relation
of subclinical infections with human growth, through possible
reduction in immunostimulation and protein diversion to acute
phase reactants, has also been recognised.10 What then are the
policy implications of Gough and colleagues’ findings? Beyond
the obvious need for the rapid diagnosis and treatment of
infections in children, the use of antibiotics for promoting
growth poses problems. Widespread use of antibiotics—usually
in feeds—to promote growth in animals is common and known
to promote antimicrobial resistance.11 Although Gough and
colleagues suggest that antibiotics might benefit intestinal
microbiota, little evidence supports this relation. It is more likely
that antibiotics have an adverse effect on intestinal
microflora.12 13 Any large scale use of antibiotics must be
weighed against the possibility of serious long term harm both
to individuals and to global populations through the emergence
of resistance.14 There are also obvious cost implications for the
commodities and delivery strategies.
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There is a clear need for further research in this area to help us
understand precisely how antibiotics might promote growth in
children. Researchers could start by characterising high risk
groups of children who might benefit, such as those with clearly
defined subclinical or overt infections, HIV, or severe acute
malnutrition. Further trials should be done to confirm the
interesting findings from Malawi.7 But extending trials of
antibiotics to other categories of children, such as those at risk
of malnutrition and growth failure, may not be justifiable at this
stage. Researchers should instead exploit existing observational
cohorts to explore the relation between infections, antibiotic
treatment, and nutrition outcomes, including growth patterns,
where data are available. The large multicentre Mal-ED studies
assessing patterns of growth among infants 0-24 months of age
across eight countries (www.fnih.org/work/key-initiatives/maled) are an excellent example of an opportunity to assess the
potential impact of antibiotic treatment on linear growth and
weight gain using standardised data and definitions. In the
interim, continued focus on the 10 recommended evidence based
nutrition interventions to promote growth15 must be prioritised.
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